Display Settings:

Format

Send to:

Choose Destination

    Transplantation. 1990 Oct;50(4):617-20.

    Bone marrow transplantation for the Wiskott-Aldrich syndrome. Long-term follow-up.

    Rimm IJ, Rappeport JM.

    Division of Pediatric Hematology-Oncology, Children's Hospital, Boston, Massachusetts.

    Wiskott-Aldrich Syndrome (WAS) is a sex-linked disease characterized by immunodeficiency and thrombocytopenia. Supportive treatment of this disease is inadequate and bone marrow transplantation has been reported to result in excellent survival. The long-term follow-up of 8 male patients who received bone marrow transplantation for the WAS is reported here. All of these patients received ablative preparative treatment consisting of ATS (antithymocyte serum), cytoxan and either busulfan or TBI (total body irradiation). Bone marrow was transplanted from an HLA-matched donor. Seven of eight of these male patients have had excellent engraftment of their transplant and now have adequate lymphocyte and platelet function. In addition, they have had good growth and development. This suggests that ablative preparative treatment followed by early bone marrow transplantation from an HLA-matched donor is a highly successful therapy for this congenital disease.

    PMID: 2219285 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Patient drug information

    • Busulfan

      Your doctor has ordered the drug busulfan to help treat your illness. The drug can be taken by mouth in the form of tablets.